Research Progress of Sodium-glucose-cotransporter-2 Inhibitors in Patients with Heart Failure with Mildly Reduced Ejection Fraction

Abstract

Sodium-glucose-cotransporter-2 (SGLT2) inhibitors originally developed as hypoglycemic agents, have been shown to reduce type 2 atherosclerotic cardiovascular disease (ASCVD) with or without heart failure hospitalization (HFH) and cardiovascular mortality risk in patients with diabetes mellitus (T2DM) . The just-concluded EMPEROR-Preserved trial evaluated the clinical efficacy of an SGLT2 inhibitor (empagliflozin) in patients with heart failure with preserved ejection fraction (HFpEF) and the results showed that its clinical effect could be further extended to heart failure mildly reduced ejection fraction (HFmrEF) patients. Although SGLT2 inhibitors have ushered in a new era of reducing HF incidence and preventing HF exacerbation, the search for key mechanisms by which SGLT2 inhibitors improve symptoms should continue to protect heart failure patients from the fatal progression of heart failure disease. This paper reviews the application of SGLT2 inhibitors in the treatment of HFmrEF patients, in order to provide theoretical guidance for the treatment of HFmrEF patients.

Keywords

• heart failure|sodium-glucose transporter 2 inhibitors|heart failure with mildly reduced ejection fraction|treatment outcome|review